INDOCO Indoco Remedies Q1 FY27 results (Apr–Jun 2026) and concall
Indoco Remedies reported a robust Q1 FY27 with consolidated revenue up 8.2% YoY and standalone EBITDA margin at 10.3%. Strong performance in US and API segments drove growth, while domestic and emerging markets faced seasonal and temporary headwinds. Gross margins were pressured by raw material costs, and the pending USFDA audit for sterile products remains a key focus for future growth in regulated markets.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 6.4%, net profit up 280.6% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 411 | 390 | 440 | 485 | 445 +8% | 476 +22% | 468 +6% |
| EBITDA | 12 | -1 | 18 | 43 | 32 +167% | 50 +5100% | 41 +128% |
| Net profit | -28 | -41 | -36 | -9 | -29 −4% | -24 +41% | 65 +281% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
